These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 34244223

  • 1. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with 68Ga-PSMA-11 PET/CT.
    Kalshetty A, Menon B, Rakshit S, Bhattacharjee A, Basu S.
    J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic value of dual-time point 68Ga-PSMA PET/CT image for benign and malignant lesions in patients with prostate cancer.
    Xiao L, Su M, Li Y.
    Abdom Radiol (NY); 2024 Sep; 49(9):3214-3219. PubMed ID: 38546825
    [Abstract] [Full Text] [Related]

  • 4. Assessing Krenning's score on 68 Ga-DOTATATE PET-CT and miPSMA score on 68 Ga-PSMA-11 PET-CT in TENIS: a comparison with FDG PET/CT and examining the feasibility of targeted radionuclide therapy.
    Sonavane S, Salvi O, Asopa RV, Basu S.
    Nucl Med Commun; 2024 Aug 01; 45(8):690-701. PubMed ID: 38832433
    [Abstract] [Full Text] [Related]

  • 5. Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.
    Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka H, Decristoforo C, von Guggenberg E, Horninger W, Virgolini IJ.
    J Nucl Med; 2021 Nov 01; 62(11):1550-1557. PubMed ID: 33712533
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes.
    Swiha M, Papa N, Sabahi Z, Ayati N, John N, Pathmanandavel S, Crumbaker M, Li S, Agrawal S, Ayers M, Hickey A, Sharma S, Nguyen A, Emmett L.
    J Nucl Med; 2024 Jun 03; 65(6):904-908. PubMed ID: 38637137
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.
    Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S.
    Cancer Biother Radiopharm; 2021 Apr 03; 36(3):292-304. PubMed ID: 32379495
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of Practical Interpretation Hurdles in 68Ga-PSMA PET/CT in 55 Patients: Physiological Tracer Distribution and Incidental Tracer Uptake.
    Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J, Rabenalt R, Antoch G, Buchbender C.
    Clin Nucl Med; 2017 Jul 03; 42(7):e322-e327. PubMed ID: 28481787
    [Abstract] [Full Text] [Related]

  • 11. Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
    Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP.
    J Nucl Med; 2022 Aug 03; 63(8):1199-1207. PubMed ID: 34887335
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W.
    Mol Imaging Biol; 2016 Jun 03; 18(3):428-36. PubMed ID: 27038316
    [Abstract] [Full Text] [Related]

  • 17. Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
    Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M.
    J Nucl Med; 2022 Feb 03; 63(2):226-232. PubMed ID: 34049987
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Initial evaluation and external validation of 68Ga-PSMA-11 PET/CT in tubarial gland characterization.
    Alvarez-Lozada LA, Salinas-Puente EJ, Torres-De León RA, Arrambide-Garza FJ, Quiroga-Garza A, Elizondo-Riojas G, Elizondo-Omaña RE, Guzmán-López S, Treviño-Gonzalez JL.
    Radiother Oncol; 2024 Jan 03; 190():109975. PubMed ID: 37913955
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.